Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial

doi:10.1186/1471-2407-6-202

BMC Cancer

Volume 6

Viewing options:

Associated material:

Related literature:

Articles citing this article
on Google Scholar
on ISI Web of Science
on PubMed Central
Other articles by authors
on Google Scholar

Pignata S
Scambia G
Savarese A
Breda E
Scollo P
De Vivo R
Rossi E
Gebbia V
Natale D
Del Gaizo F
Naglieri E
Ferro A
Musso P
D'Arco AM
Sorio R
Pisano C
Di Maio M
Signoriello G
Annunziata A
Perrone F

on PubMed

Pignata S
Scambia G
Savarese A
Breda E
Scollo P
De Vivo R
Rossi E
Gebbia V
Natale D
Del Gaizo F
Naglieri E
Ferro A
Musso P
D'Arco AM
Sorio R
Pisano C
Di Maio M
Signoriello G
Annunziata A
Perrone F
Related articles/pages
on Google

on Google Scholar

on PubMed

Tools:

Post to:

Email this article to a friend

Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial

Sandro Pignata , Giovanni Scambia , Antonella Savarese , Enrico Breda , Paolo Scollo , Rocco De Vivo , Emanuela Rossi , Vittorio Gebbia , Donato Natale , Filomena Del Gaizo , Emanuele Naglieri , Antonella Ferro , Pietro Musso , Alfonso Maria D'Arco , Roberto Sorio , Carmela Pisano , Massimo Di Maio , Giuseppe Signoriello , Annalisa Annunziata and Francesco Perrone for the MITO Investigators (see appendix)

BMC Cancer 2006, 6:202doi:10.1186/1471-2407-6-202

Your name*
Your email address*
Recipient's email address*	(multiple email addresses should be separated with commas)
Email format
Please type your message into the box below:	I thought the following article from BMC Cancer (http://www.biomedcentral.com/home) would be of interest to you.